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Insulin receptor substrates 1 and 2 but not Shc can activate the
insulin receptor independent of insulin and induce proliferation
in CHO-IR cells
Abstract
Ligand-activated insulin receptor (IR) attracts and phosphorylates various substrates such as insulin
receptor substrates 1-4 (IRS) and Shc. To investigate how binding affinity for substrate affects
signalling we generated chimeric receptors with the beta-chain of the insulin receptor containing NPXY
motives with different affinities for receptor substrates. We found that the extent of receptor tyrosine
phosphorylation positively correlates with binding affinity towards IRS1/2 but not towards Shc.
Moreover, overexpression of IRS1 or IRS2 but not of Shc increased IR tyrosine phosphorylation in a
dose-dependent manner, also independent of insulin. Molecular truncations of IRS1 revealed that neither
the isolated PH and PTB domains nor the C-terminus with the tyrosine phosphorylation sites alone are
sufficient for substrate-dependent receptor activation. Overexpression of IRS1 and IRS2 impaired
insulin-induced internalization of the IR in a dose-dependent manner suggesting that IRS proteins
prevent endosome-associated receptor dephosphorylation/inactivation. IRS1 and IRS2 could therefore
target the activated IR to different cellular compartments. Overexpression of IRS1 and IRS2 inhibited
insulin-stimulated activation of the MAP kinases Erk1/2 while it increased/induced activation of
Akt/PKB. Finally, overexpression of IRS1 and IRS2 but not of Shc induced DNA synthesis in starved
CHO-IR cells independent of exogenous growth factors. Our results demonstrate that variations in
cellular IRS1 and IRS2 concentration affect insulin signalling both upstream and downstream and that
IRS proteins could play instructive rather than just permissive roles in signal transmission.
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Abstract 
Ligand-activated insulin receptor (IR) attracts and phosphorylates various substrates 
such as insulin receptor substrates 1-4 (IRS) and Shc. To investigate how binding 
affinity for substrate affects signalling we generated chimeric receptors with the β-
chain of the insulin receptor containing NPXY motives with different affinities for 
receptor substrates. We found that the extent of receptor tyrosine phosphorylation 
positively correlates with binding affinity towards IRS1/2 but not towards Shc. 
Moreover, overexpression of IRS1 or IRS2 but not of Shc increased IR tyrosine 
phosphorylation in a dose-dependent manner, also independent of insulin. Molecular 
truncations of IRS1 revealed that neither the isolated PH and PTB domains nor the 
C-terminus with the tyrosine phosphorylation sites alone are sufficient for substrate-
dependent receptor activation. Overexpression of IRS1 and IRS2 impaired insulin-
induced internalization of the IR in a dose dependent manner suggesting that IRS 
proteins prevent endosome-associated receptor dephosphorylation/inactivation. IRS1 
and IRS2 could therefore target the activated IR to different cellular compartments. 
Overexpression of IRS1 and IRS2 inhibited insulin-stimulated activation of the MAP 
kinases Erk 1/2 while it increased/induced activation of Akt/PKB. Finally, 
overexpression of IRS1 and IRS2 but not of Shc induced DNA synthesis in starved 
CHO-IR cells independent of exogenous growth factors. Our results demonstrate that 
variations in cellular IRS1 and IRS2 concentration affect insulin signalling both 
upstream and downstream and that IRS proteins could play instructive rather then 
just permissive roles in signal transmission. 
 
Keywords: Insulin signalling, insulin receptor, insulin receptor substrate, IRS1, IRS2, 
Shc, CHO-IR, proliferation. 
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Introduction 
Insulin action (reviewed by [1]) depends on the activation of the Insulin Receptor (IR), 
a tetrameric transmembrane tyrosine kinase (RTK) consisting of two extracellular α- 
and two intracellular β-subunits with the RTK residing on the β-subunits. Binding of 
insulin to the α-subunits results in rapid autophosphorylation of several tyrosine 
residues in the intracellular part of the receptor [2, 3]. The autophosphorylation sites 
are clustered in three regions. Two sites reside within the juxtamembrane region, 
three within the regulatory loop of the kinase and two within the COOH-terminal tail. 
The tyrosine clusters have different roles in the propagation of the insulin signal: 
First, phosphorylation of the regulatory loop is required for full activation of the RTK. 
The activated kinase then phosphorylates the tyrosine residue within the sequence 
NPEY located in the juxtamembrane region. This NPEY motif is a variation of the 
consensus binding site (NPXY) for phosphotyrosine binding (PTB) domain-containing 
proteins. Once phosphorylated it attracts receptor substrates which contain a PTB 
domain, like the insulin receptor substrate (IRS) proteins and Shc [4]. In addition to 
the recruitment of receptor substrates, phosphorylation of the NPEY motif in the 
juxtamembrane region of the IR is required for insulin-induced receptor endocytosis 
[5]. The role of the third tyrosine cluster in the COOH-terminal tail of the IR is not fully 
understood but it seems to be required for fine-tuning of the kinase activity [6], and 
eventually recruits signalling components with SH2 domains such as Grb10 [7].  
Besides the IR, also the activated Interleukin-4 (IL-4) receptor recruits IRS proteins 
via a NPXY (NPAY) motif. This raises the question of how these different receptors 
can transmit specific signals through the same receptor substrates. Previous work 
suggests that the NPAY motif found in the IL-4 receptor binds the PTB domain of 
IRS1 about 30 times stronger compared to the NPEY motif of the IR [8, 9].  
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Two major pathways are activated downstream of insulin receptor substrates: Grb2 
induces the MAP kinase cascade resulting in the activation of Erk1 and Erk2 
(p42/p44) through phosphorylation of threonine 202 and tyrosine 204 [10, 11]. The 
regulatory subunit (p85) of PI 3´ kinase (PI3K) stimulates the synthesis of PI3,4,5P3 
and finally leads to activation of the serine-threonine kinase Akt/PKB. Akt activation 
requires phosphorylation of threonine 308 and serine 473 [12].  
We hypothesized that the steady-state level of the receptor-substrate complex could 
influence signal propagation. In this study we show that modulating the affinity 
between receptor and substrates affects the phosphorylation state of both, the 
receptor and its substrate. In addition we present evidence that overexpression of 
IRS1 and IRS2, but not of Shc can mimic insulin action in CHO-IR cells which might 
in part depend on the inhibition of receptor-endocytosis. 
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Experimental procedures 
Reagents and Antibodies 
Chemicals were purchased from SIGMA (Buchs, Switzerland) unless otherwise 
mentioned. Human recombinant M-CSF was obtained from Calbiochem (JURO, 
Lucerne, Switzerland), bovine insulin from SIGMA and [125I]-insulin from Amersham 
Pharmacia (Dübendorf, Switzerland). Antibodies against phosphotyrosine (PY99), the 
insulin receptor β-subunit, IRS1, IRS2, Shc and Rabbit anti-Grb2 (C-23) were 
purchased from Santa Cruz Biotechnology Inc. Antibodies against phospho-Akt, 
phospho-Erk 1/2 and p85 were obtained from Cell Signaling (Beverly, USA). 
Cell Culture and Treatments 
Cell culture media and other reagents were purchased from Gibco BRL. HEK 293 
cells and CHO-K1 cells were a gift of the Department for Calcium Metabolism, Zurich. 
They were grown in DMEM supplemented with 10 % FBS (HEK 293 cells) or HAM 
F12 supplemented with 10 % FBS (CHO K1 cells). CHO-IR cells were a gift of Jeffery 
E. Pessin (Iowa City, USA) and were grown in HAM F12 supplemented with 10 % 
FBS. All cells were grown at 37 °C and 5 % CO2, and in the presence of 100 U/ml 
penicillin and 100 μg/ml streptomycin (Gibco BRL). 
Cells were transfected with plasmid DNA in 6 or 24 well plates after they reached 80-
90 % confluence using Lipofectamine 2000 (Gibco BRL). CHO-K1 cells were 
harvested 24 h and HEK 293 cells 48 h post transfection for further analysis.  
Plasmids and adenoviral vectors 
We generated the CSF/IR chimeric receptor as described by Chaika et al. [13]. After 
subcloning into the expression vector pCMV Transfer mutations were introduced into 
the isolated Bsu36 I - Xho I fragment of the CSF/IR chimeric receptor by polymerase 
chain reactions. The cDNA of the human insulin receptor was subcloned into 
pcDNA3.1 (Invitrogen, Groningen, The Netherlands). The expression constructs 
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encoding human Shc, human IRS1, and mouse IRS2 have been described 
previously [14].  
Co-Immunoprecipitation, Ni-NTA purification and Western Blotting 
HEK 293 cells were transfected in 6 well plates with a plasmid mixture containing 
1.25 μg of expression vector coding for myc-tagged IRS1, IRS2 or Shc, respectively 
and additionally 1.25 μg of plasmid either encoding a respective mutant chimeric 
receptor or GFP. 44 h post transfection, cells were serum deprived for 4 h in DMEM 
containing 0.5 % BSA and subsequently stimulated for 10 min with 10 nM M-CSF. 
Thereafter, cells were lysed in lysis buffer (20 mM Tris pH 7.5, 100 mM NaF, 1 % NP-
40, 5 mM EDTA) freshly supplemented with 1 mM PMSF, 3 mg/ml aprotinin, 3 mg/ml 
leupeptin, 1 mM Na2H2P2O7, and 1 mM Na3O4V. Precleared lysates were incubated 
with 0.5 μg of α-insulin receptor β-chain antibody for 1 h at 4 °C under constant 
shaking. 20 μl of immobilized protein A on trisacryl (Pierce, Rockford, USA), 
equilibrated in lysis buffer were added to the cell lysates and equilibrated over night 
at 4 °C on a rotating wheel. Thereafter beads were collected by a short centrifugation 
and washed 3 times with cold PBS. Finally, 20 μl of 1.5x SDS gel loading buffer (75 
mM Tris/HCl, pH 6.8, 3% SDS, 15% glycerol, 0.15 % bromophenolblue, 7.5 % 2-
mercaptoethanol) were added, samples were boiled for 3 min and beads were 
removed by short centrifugation. Supernatants were separated on SDS-PAGE.  
For pull-down experiments with Ni-NTA CHO-IR cells were grown on 10 cm plates 
and infected with adenoviral vectors encoding myc-HIS-tagged IRS1, IRS2, Shc or 
GFP as a control. After 48 hours cells were washed with PBS and starved in 
appropriate medium as described for HEK293 cells. If required insulin was added for 
4 minutes followed by 3 washes with ice-cold PBS. Cells were lysed in 100 mM 
HEPES, 0.5 % Triton X-100, 150 mM NaCl in the presence of protease and 
phosphatase inhibitors. Affinity purification of HIS-tagged IRS1, IRS2 and Shc using 
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Ni-Agarose (Ni-NTA) was essentially as described by the manufacturer (Qiagen). 
After elution with 300 mM imidazol proteins were separated by SDS-PAGE. 
Separated proteins were transferred to Protran BA 85 Cellulosenitrate membranes 
(Schleicher &Schuell, Dassel, Germany) using a Trans-Blot® Semi-Dry Transfer Cell 
(BIO-RAD, Glattbrugg, Switzerland). Immunodetection was carried out according to 
the instructions of the manufacturers of the antibodies. Secondary antibodies coupled 
to horseradish peroxidase and the Lumi-Light Western Blotting Substrate (Roche 
Diagnostics, Mannheim Germany) was used for signal detection. 
Insulin Receptor Internalization in CHO-IR Cells 
Confluent CHO-IR cells on gelatin-coated 24 well plates were infected with 
adenoviral vectors encoding IRS1, IRS2 or Shc. 24 h after transfection, the medium 
was replaced with medium lacking serum but supplemented with 0.5 % BSA for 4 h. 
Thereafter cells were transferred to an ice-water bath to interrupt receptor 
translocation and 50'000 CPM of [125I]-insulin were added. Ligand-receptor binding 
was equilibrated at 4 °C for 1 h. In some experiments 0.4 M ice-cold sucrose was 
added for the final 20 min of equilibration to block subsequent receptor endocytosis 
[15-17]. To allow receptor endocytosis, cells in suspension were warmed to 37°C for 
20 min before the reaction was stopped on ice-water. Unbound [125I]-insulin was 
washed off three times with ice-cold PBS. [125I]-insulin bound to surface-exposed 
receptors was extracted with two washes of ice-cold stripping buffer (0.2 M glycine 
pH 2.2, 0.5 M NaCl). The two extracts were pooled and analysed in a γ-counter. 
Internalized [125I]-insulin was determined in lysates of stripped cells. The rate of 
endocytosis was calculated as ratio of the radioactivity in the two low pH extractions 
and the radioactivity in the lysates. 
Thymidine incorporation assays 
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CHO-IR cells on 24 well plates (80-90% confluent) were infected in triplicates with 
adenoviral vectors (1-5 x 106 pfu/well). After 5 h, the culture medium was replaced 
with 0.5 ml of HAM F12 containing no serum but 0.5 % BSA for 2 h (starvation 
medium). Insulin at various concentrations was added to the starvation medium and 
cells were cultured at 37 °C under 5 % CO2 for 16 h. Finally, [3H]-thymidine (89 
Ci/mmol, 220'000 cpm) was added and thymidine incorporation was stopped after 4 h 
by washing the adherent cells 3 times with ice-cold PBS followed by the addition of 
10 % (w/v) TCA and incubation for 30 min at 4 °C. Precipitates were washed with 10 
% TCA to remove unincorporated thymidine, air-dried, and finally resuspended in 300 
μl of neutralizing 1 M KOH. [3H]-thymidine incorporated into DNA was assessed by 
liquid scintillation counting. Expression of transgenes was confirmed for each 
experiment by Western blot analysis.  
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Results 
Receptors with different variations of the juxtamembrane NPXY motif are 
differentially tyrosine phosphorylated 
We introduced mutations into the NPEY motif within the insulin receptor to modulate 
its affinity for IRS-proteins, and studied how this modulation affects signal 
transduction. To exclude ligand-specific effects and in order to distinguish mutated 
receptors from endogenous insulin receptors we generated chimeric receptors 
consisting of the extracellular domain of the CSF-1 receptor and the intracellular 
portion of the insulin receptor (CSF/IR) [13]. Exposure of transfected cells to M-CSF 
dose-dependently increased autophosphorylation of chimeric receptors (data not 
shown). Chimeric receptors with the following NPXY (PTB domain-binding) motifs 
were generated: i) NPEY, as found in the insulin receptor; ii) NPEF, which can not be 
phosphorylated and hence eliminates phosphorylation-induced binding of the PTB 
domain [2, 8]; iii) NPAY, corresponding to the motif found in the IL-4 receptor, which 
binds the IRS1 PTB domain 30-fold stronger compared to the NPEY motif; and iv) 
APEY, that exhibits no binding in a peptide binding assay [9]. To confirm the 
previously described effects of these different mutations on complex formation 
between chimeric receptor and IRS proteins, we tested the receptor-substrate 
interactions by co-immunoprecipitations. The CSF/IR chimeric receptors were co-
expressed with constant amounts of myc-tagged IRS1 in 293 cells. After stimulation 
with 10 nM M-CSF for 10 min cells were lysed, and chimeric receptors were 
immunoprecipitated with an antibody recognizing the β-chain of the insulin receptor. 
The amount of co-precipitated IRS1 was assessed by immunoblotting with an 
antibody against the myc tag. As shown in Fig.1A, in the absence of chimeric 
receptors, no myc-tagged IRS1 could be co-precipitated with the antibody against the 
insulin β-chain. Together with the receptor containing the NPEY motif considerable 
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amounts of IRS1 were co-precipitated in the absence of extracellular ligand. Co-
precipitation of IRS1 was increased 2-3 times after stimulating cells with M-CSF. 
Different results were obtained with chimeric receptors containing the NPEF motif. In 
the absence of M-CSF co-precipitation of IRS1 was similar to levels observed with 
NPEY-containing receptors. However, exposure of cells to M-CSF did not increase 
co-precipitation of IRS1. In contrast, receptors containing NPAY co-precipitated 
around 4 times more IRS1 in the absence and 2 times more in the presence of M-
CSF compared to receptors containing the NPEY motive, respectively. Almost no 
IRS1 was co-precipitated with receptors containing the APEY motif, independent of 
stimulation with M-CSF. These results correspond well with the previously 
determined relative affinities of peptides with respective NPXY motives towards the 
PTB domain in vitro [9].  
In the course of the above experiments we noticed that the degree of tyrosine 
phosphorylation (Fig. 1A lowest panel) of the chimeric receptors not only correlated 
with ligand stimulation, but also with affinity for IRS1. Receptors containing a high 
affinity-binding motif such as NPAY, and NPEY revealed a more pronounced tyrosine 
phosphorylation than receptors with a low affinity binding motif (APEY, NPEF), 
remarkably, even in the absence of ligand stimulation. A quantification of the results 
is shown in Fig. 1B.  
Overexpression of IRS1 and IRS2 but not of Shc increases insulin receptor 
tyrosine phosphorylation in a dose-dependent manner 
Because our results suggested that increasing the affinity between receptor and 
substrate can augment receptor phosphorylation independent of the presence of the 
extracellular ligand we tested whether receptor phosphorylation was proportional to 
increasing concentrations of substrates. For this purpose a constant amount of 
plasmid coding for the wild type insulin receptor was co-transfected into CHO-K1 
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cells with increasing amounts of plasmid encoding IRS1, IRS2, or Shc. Cells were 
lysed, and the amount of tyrosine phosphorylated protein was evaluated by Western 
blotting using antibodies against phosphotyrosine residues (Fig. 2A). The expression 
level of the exogenous insulin receptor was kept constant in all transfectants whereas 
the level of the receptor substrates IRS1, IRS2 and Shc increased dependent on the 
transfected amount of corresponding expression plasmids (Fig. 2B). The results 
shown in Fig. 2A demonstrate that the extent of insulin receptor tyrosine 
phosphorylation in the absence and in the presence of 100 nM insulin increased with 
increasing levels of IRS1. This induction of receptor phosphorylation by its substrate 
was significant as it even exceeded receptor tyrosine phosphorylation after exposure 
to 100 nM insulin in the absence of exogenous IRS1. While IRS2 induced receptor 
phosphorylation similar to IRS1 (Fig. 2A), no dose-dependent increase but rather a 
decrease in insulin receptor tyrosine phosphorylation was detected if Shc was 
overexpressed (Fig. 2A), although the cellular content of Shc was substantially 
increased in transfectants (Fig. 2B). Shc was strongly tyrosine phosphorylated (Fig. 
2A) which suggests that the ectopically expressed protein was functional.  
 
The role of the various domains of IRS1 in insulin receptor tyrosine 
phosphorylation 
In order to determine the essential domains of IRS1 that are required for the 
stimulatory effect on the IR we co-expressed myc-tagged truncations of IRS1 and the 
full-length IR in CHO-K1 cells. The various fragments of IRS1 used for this 
experiment are shown in Fig. 3A. Immunoblotting with a myc-specific antibody 
showed that the truncations were expressed to the same level as full-length IRS1-
myc (Fig. 3B and C, lower panel). The expression of exogenous insulin receptor 
remained constant in all transfectants (middle panel). Neither IRS1(C-term) nor 
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IRS1(PH-PTB) stimulated receptor tyrosine phosphorylation, although IRS1(C-term) 
was tyrosine phosphorylated at high expression levels (Fig. 3C, top panel). Moreover, 
at high expression levels IRS1(PH-PTB) repressed insulin-induced tyrosine 
phosphorylation of the IR beta chain. IRS1(ΔPH) was strongly tyrosine 
phosphorylated at high expression levels, comparable to full-length IRS1 (Fig. 3B). 
However, exposure of the cells to 100 nM insulin only marginally further increased 
substrate tyrosine phosphorylation. IRS1(ΔPH) augmented insulin receptor tyrosine 
phosphorylation but to a lesser extent than full-length IRS1 (Fig. 3B). Finally, also 
overexpressed IRS1(ΔPTB) was significantly tyrosine phosphorylated, but to a lesser 
extent than IRS1(ΔPH). In addition, deletion of the PTB domain reduced the 
stimulation of receptor tyrosine phosphorylation more pronounced than deletion of 
the PH domain (Fig. 3B). 
 
Overexpression of IRS1 and IRS2 decreases the rate of insulin receptor 
endocytosis 
Dephosphorylation of the IR following insulin stimulation is thought to depend on 
receptor internalization. To assess if overexpression of IRS1/2 and Shc influence 
receptor internalization the rate of [125I]-insulin endocytosis in CHO-IR cells was 
determined. Cells were transfected with adenoviral vectors encoding myc-tagged 
IRS1, IRS2 or Shc, and insulin internalization was measured 24 h post infection. 
Since adenoviral infection and different virus titers might affect receptor 
internalization similar experiments were performed with lipofectamine-based 
transfection of IR-substrates. The results were comparable to adenoviral infections. 
In addition, adenoviral overexpression of IRS1/2 (but not of Shc) induced activation 
of the IR similar to lipofectamine-based overexpression (not shown). As shown in Fig. 
4A, infection with control virus encoding GFP did not alter the internalization rate of 
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insulin compared to uninfected cells. However, overexpression of IRS1 and of IRS2 
resulted in a significant and dose-dependent decrease in the internalization rate. Shc 
had a much weaker effect on receptor internalization even though its expression 
levels were high (Fig. 4A, right panel). The cellular content of insulin receptor was not 
affected by adenoviral overexpression of GFP, IRS1, IRS2, and Shc (data not 
shown).  
To test if decreased receptor endocytosis per se could increase receptor tyrosine 
phosphorylation, we inhibited cellular endocytosis by hyperosmolar sucrose [15-17] 
and assessed tyrosine phosphorylation of the insulin receptor. 0.4 M sucrose 
reduced receptor endocytosis more than 6-fold (Fig. 4A). Serum-deprived CHO-IR 
cells were incubated with 10 nM insulin for 0 to 30 min and equal amounts of cell 
lysates were analysed on Western blots (Fig. 4B). At all time points insulin caused a 
pronounced increase in receptor tyrosine phosphorylation. Pre-treatment with 0.4 M 
sucrose alone was not sufficient to induce tyrosine phosphorylation of the IR but 
sucrose synergistically increased phosphorylation of the IR in combination with 
insulin. As shown in the lower panel of Fig. 4 the expression levels of the IR were 
unaffected by sucrose treatment. The above experiments suggest that substrate-
induced tyrosine phosphorylation of the insulin receptor could in parts dependent on 
decreased insulin receptor internalization but inhibition of internalization per se is not 
sufficient to activate the receptor. 
Differential effects of IRS1, IRS2 and Shc on the activation of Akt/PKB and 
Erk1/2 
In order to investigate if substrate-mediated receptor activation affects downstream 
signalling events we assessed the activation of Akt/PKB and ERK1/2. CHO-K1 cells 
were transiently co-transfected with constant amounts of expression plasmids 
encoding insulin receptor and myc-tagged IRS1, IRS2 and Shc, respectively. 20 h 
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post transfection cells were serum-deprived for additional 4 h and then stimulated for 
4 minutes with different concentrations of insulin as indicated prior to protein 
extraction for immunoblotting (Fig. 5A) with specific antibodies against Akt/PKB 
phosphorylated at serine 473 and ERK1/2 phosphorylated at threonine 202 and 
tyrosine 204, respectively. Control experiments revealed that similar amounts of the 
insulin receptor were present in all cell lysates. Comparable amounts of the three 
insulin receptor substrates were detected in the lysates from cells that were 
transfected with corresponding vectors (data not shown).  
The combination of insulin challenge and simultaneous overexpression of insulin 
receptor substrates revealed two phases with respect to Akt/PKB activation (Fig. 5A 
top lane). Up to concentrations of 0.5 nM insulin, overexpression of IRS1 or IRS2 and 
hormonal stimulation synergistically increased the activation of Akt/PKB. IRS2 was 
slightly more potent than IRS1, although IRS2 was less abundant in the experiment 
shown (Fig. 5A, lane 4). Upon stimulation with 2 or 10 nM insulin no additional 
increase in the phosphorylation of Akt/PKB was observed with overexpression of 
IRS1 or IRS2. In contrast to IRS1 and IRS2 Shc did not affect Akt/PKB activation at 
any insulin dose.  
Overexpression of insulin receptor substrates affected the activation of Erk1/2 
differently compared to the activation of Akt/PKB (Fig. 5, lane 2). At low insulin 
concentrations (0.02 and 0.1 nM), overexpression of IRS1, IRS2 and Shc did not 
substantially alter the insulin-induced phosphorylation of Erk1/2. However, at higher 
hormone concentrations, IRS2 and to a smaller extent IRS1 inhibited activation of 
ERK1/2, whereas Shc showed no effect compared to control cells that were 
transfected with GFP.  
Insulin-induced activation of ERK1/2 requires recruitment of Grb2 to receptor 
substrates while activation of Akt/PKB depends on p85, the regulatory subunit of 
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PI3K. We affinity purified ectopically expressed HIS-tagged IRS1, IRS2 and Shc from 
starved or insulin-stimulated CHO-IR cells using Ni-NTA. Eluates were then analysed 
by Western blotting with antibodies against Grb2 and p85 in order to test if they co-
purify with receptor substrates. Results are presented in Fig. 5B. p85 co-purified with 
ectopically expressed IRS1 and IRS2 to the same extend from lysates of starved and 
insulin-stimulated CHO-IR cells. Co-purification of p85 was undistinguishable 
between Shc and GFP expressing cells, indicating that only very little or no p85 is 
bound to ectopically expressed Shc. Quantification of signal intensities shows that 
around 5 fold more p85 co-purified with IRS1/2 compared to Shc or GFP. Grb2 only 
co-purified with IRS1/2 and Shc when cells had been stimulated with insulin but not 
after starvation. About 2-3 times more Grb2 was bound to Shc than to IRS1/2. Similar 
results were obtained with immunoprecipitation experiments (not shown). 
 
 
Overexpression of IRS1 and IRS2 but not of Shc induces proliferation in CHO-
IR cells  
In a last series of experiments we assessed insulin-dependent proliferation in CHO-
IR cells by measuring [3H]-thymidine incorporation after overexpression of insulin 
receptor substrates. Fig. 6 A summarizes our results after overexpression of IRS1, 
IRS2 or Shc. In five independent experiments overexpression of IRS1 and IRS2 but 
not of Shc induced DNA replication independent of insulin. The levels of ectopic 
expression were similar for all receptor substrates (not shown). At insulin 
concentrations of 0.5 and 5 nM both IRS1 and IRS2 enhanced proliferation 
synergistically with hormone. At 50 nM insulin the proliferation rate was already 
maximal and could hence not be further enhanced by overexpression of IRS1/2. In 
contrast, Shc slightly repressed insulin-induced [3H]-thymidine incorporation. 
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Immunoblots confirmed that adenovirus-based overexpression of IRS1 and IRS2 but 
not of Shc induced/increased the activation of Akt/PKB as in our previous 
experiments described above after transfection of plasmid DNA using Lipofectamine.  
To further delineate the mitogenic effect of IRS proteins, subfragments of IRS1 were 
transfected into CHO-IR cells (Fig. 6B). Overexpression of the PH-PTB domain alone 
repressed basal and insulin (5 nM)-induced [3H]-thymidine incorporation significantly 
while all other fragments did not significantly differ from GFP, indicating that the 
former fragment interferes with the stimulatory effect of full length IRS proteins by 
competing for the receptor binding. To test this hypothesis GFP or full length IRS1 
was simultaneously overexpressed together with the PH-PTB or the C-terminal 
fragment of IRS1 (C-term). Results are shown in Figure 6C. As in previous 
experiments full length IRS1 but neither GFP nor the C-terminal fragment of IRS1 
stimulated thymidine incorporation at 0 and 5 nM insulin. The PH-PTB domain 
inhibited DNA replication in the absence and presence of insulin. In addition it 
competed with the stimulatory effect of full length IRS1 and reduced its potential to 
enhance thymidine incorporation. Interestingly, although the C-terminal fragment by 
itself did not affect thymidine incorporation it diminished the stimulation by full length 
IRS1, presumably by competing with full length IRS1 for downstream signalling 
components.  
 
 
Discussion 
Insulin receptor substrates are usually viewed as unidirectional signal transmitters 
that receive stimuli from upstream receptors and forward them to downstream 
effectors. Our results now suggest that IRS1 and IRS2, but not Shc, can also send 
information upstream to the receptor. IRS1 and IRS2 can activate the IR independent 
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of prior hormonal stimulation and they are able to potentiate insulin-dependent 
activation.  
In response to CSF-1 CSF-1/IRβ chimeric receptors that contained modified binding 
motifs (NPXY) for the PTB domain in insulin receptor substrates were tyrosine 
phosphorylated depending on binding affinity for their substrates. Receptors with the 
high affinity binding motif NPAY were hyperphosphorylated compared to receptors 
with the low affinity NPEY motif. Hence high affinity binding of IRS proteins to the 
receptor enhances its tyrosine phosphorylation. Our observations were not restricted 
to CSF/IR chimeric receptors. Chimeric receptors consisting of the extracellular 
domain of the EGF receptor and the intracellular domain of the insulin receptor [18] 
containing the same mutations within the NPXY motif showed similar results (data 
not shown). 
We also demonstrate that the tyrosine phosphorylation state of the insulin receptor 
correlates with the cellular concentration of IRS1 and IRS2. Since insulin receptor 
activity is directly proportional to the extent of its tyrosine phosphorylation [19] we can 
conclude that the receptor substrates do not only passively forward signalling 
information but that they can directly augment receptor kinase activity and thereby 
probably intensify signal transduction. However, not every substrate that interacts 
with the NPXY motif in the intracellular domain of the insulin receptor is also able to 
control receptor activity. Although Shc was overexpressed at similar levels compared 
to IRS1/2 it failed to affect receptor tyrosine phosphorylation. Because the ectopically 
expressed Shc protein was tyrosine phosphorylated it probably served as an insulin 
receptor substrate, as indicated by its tyrosine phosphorylation (Fig. 2A) and we 
therefore conclude that it was functional. In contrast, at high expression levels IRS1 
and IRS2 stimulated insulin receptor tyrosine phosphorylation to a similar extend as 
stimulation with the ligand insulin. Such insulin-independent but substrate-induced 
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activation of the IR kinase has to our knowledge not been reported before. However, 
Solow and co-workers [20] described previously that IRS1 but not IRS2 can increase 
insulin-induced tyrosine phosphorylation of the IR in 32B cells.  
Our findings raise the question about the mechanism by which receptor substrates 
that lack enzymatic activity enhance tyrosine phosphorylation of transmembrane 
receptors, and secondly, if substrate-initiated receptor activation induces similar 
downstream signalling events as extracellular ligand-dependent activation. Insulin 
activates ERK1/2 and to a lesser extend Akt/PKB in CHO-IR cells. In contrast, 
overexpression of IRS1 or IRS2 activated Akt/PKB but repressed activation of 
ERK1/2. This observation strongly indicates that activation of the IR by insulin and 
IRS1/2 are not equivalent events. Indeed, our pulldown experiments with CHO-IR 
cells overexpressing receptor substrates (Fig. 5B) suggest that with or without insulin 
stimulation overexpressed IRS1 and IRS2 associate with PI3K (p85) to activate the 
Akt/PKB branch of signal transduction. Shc did not associate with p85 which is 
consistent with the finding that overexpression of Shc did not activate Akt/PKB. This 
observation is consistent with our finding that overexpression of IRS1 and IRS2 
activates the IR similar to insulin stimulation. On the other hand, Grb2 which links 
insulin signalling to the Ras/ERK pathway only co-purified with IRS1/2 and, more 
strongly, with Shc after stimulation with insulin. Higher affinity of Grb2 to Shc than to 
IRS1/2 suggests that Shc is normally recruited to activate ERK in CHO-IR cells 
downstream of insulin. Ectopically expressed IRS1/2 might therefore compete with 
Shc for binding to Grb2 and thereby interfere with insulin-induced activation of 
ERK1/2. As described previously, activation of Akt/PKB can be mitogenic [21, 22] 
which is consistent with our observation that overexpression of IRS1 and IRS2 in 
CHO-IR cells increases proliferation (Fig. 6). It could therefore be that in our system 
the activation of Akt/PKB might be epistatic to repression of activation of ERK1/2.  
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We show that IRS1 and IRS2 can prevent internalization of the IR (Fig. 4) and this 
might in part underlie substrate-induced receptor activation. Inhibition of 
internalization per se does, however, not trigger receptor activation, since incubation 
of cells with sucrose did not result in receptor phosphorylation. Receptor endocytosis 
and hence receptor compartmentalization are important for the termination of ligand 
induced signalling but also for correct spatial organization of signal propagation [23-
26]. Dynamic compartmentalization and endosome-related 
dephosphorylation/inactivation of the receptor might be changed after overexpression 
of IRS1 and IRS2 and such substrate-triggered prolonged activity of the IR in specific 
cellular compartments might explain the difference in ligand versus substrate 
stimulation. Our finding is consistent with results obtained by Solow and co-workers 
[20] who suggested that IRS1 might increase tyrosine phosphorylation of the IR by 
inhibiting protein phosphatases.  
To elucidate the molecular difference between IRS1/2 and Shc and to delineate the 
domains that are involved in receptor stimulation we used truncated forms of IRS1. 
Deletion of the PH or the PTB domain from IRS1 resulted in far weaker activation of 
the IR compared to full-length IRS1 (Fig. 3). In addition, parts of the C-terminus of 
IRS1 are required that are beyond amino acid 517. This is in accordance with 
previous findings [20] showing requirement for tyrosine phosphorylation of sequences 
within the IRS1 C-terminus. Our observations extend that notion and indicate that the 
C-terminus alone without the PH-PTB domains is not sufficient and that a fragment of 
IRS1 only encompassing the PH-PTB domains without the C-terminus even 
represses insulin-induced phosphorylation of the IR (Fig. 3). Although Shc has a PTB 
domain that is structurally and functionally similar to the PH and PTB domains of IRS 
[27, 28] and althoug it serves as target for tyrosine kinases Shc is unable to stimulate 
IR tyrosine phosphorylation in CHO cells. In contrast to IRS proteins Shc lacks an 
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extended domain with multiple tyrosine phosphorylation sites. The decisive role of the 
extended C-terminus of IRS proteins in IR activation and its absence in Shc protein 
might explain why Shc is ineffective in stimulating tyrosine phosphorylation of the IR 
and to affect activation of Akt and Erk1/2.  
The roles of the different parts of IRS1 were also evaluated in thymidine incorporation 
assays (Fig. 6). Only full length IRS1 and IRS2 but not Shc were able to enhance 
DNA synthesis in the absence or in the presence of insulin. As expected from its 
ability to bind to the IR, IRS1(PH-PTB) reduced the mitogenic effect of both, 
ectopically expressed full-length IRS1 and of insulin presumably by competing with 
full-length IRS for binding to the receptor. Surprisingly, although IRS1(C-term) is not 
expected to bind to the IR, because it lacks the N-terminal PH-PTB domains, this 
fragment also inhibited thymidine incorporation induced by overexpression of full 
length IRS1 (Fig. 6C) and IRS2 (not shown). We found that this fragment was 
strongly tyrosine phosphorylated in the absence of insulin (Fig. 3C) and it might 
hence attract phosphotyrosine binding proteins thereby competing with the correct 
spatial activation of effectors for DNA replication. The observation that the C-terminal 
fragment of IRS1 impairs IRS1-induced but not insulin-induced thymidine 
incorporation implies that the signalling cascades that are activated by the ligand or 
the substrate differ either in their composition or spatial organization. This notion is 
further supported by results with other truncated IRS1 fragments. Expression of 
IRS1(1-571), IRS1(ΔPH) and IRS1(ΔPTB) at the highest levels induced insulin-
independent phosphorylation of the IR beta chain (Fig. 3) but, remarkably, these 
fragments did not induce proliferation, neither in the absence of nor synergistically 
with insulin. Therefore, activation of the IR appears to be required but not sufficient 
for mitogenicity, and probably interaction with full-length IRS proteins in a specific 
compartment is required.  
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The roles of IRS1 and IRS3 in cell cycle progression of CHO-IR cells has been 
studied previously by Kaburagi and co-workers [29]. These authors generated stable 
cell lines ectopically expressing either IRS1 or IRS3. Their major finding was that 
IRS3 antagonized insulin-induced cell cycle progression. IRS1 showed either no or 
only minor stimulatory effects. The fact that IRS1 had no major effect on proliferation 
might be explained by a rather low level of ectopic IRS1 in stable transfectants. The 
more pronounced effect of IRS1 (and IRS2) in our study might be explained by 
ectopic expression that greatly exceeded endogenous levels in transient 
transfectants (Fig. 2B). Interestingly, and in support of our observations IRS3, that 
lacks a major C-terminus in comparison to IRS1 and IRS2, did not stimulate but 
inhibited cell cycle progression probably because it competed with endogenous IRS1 
and IRS2 for binding to the IR and thus interrupted its mitogenic signal transmission. 
We had previously shown [14] that overexpression of IRS2 induces proliferation and 
represses apoptosis in pancreatic β-cells. Moreover, growth factors such as insulin, 
D-glucose and the incretin GLP-1 [30, 31] upregulate levels and phosphorylation 
state of IRS2 in β-cells. This is believed to be critical for maintenance and a 
compensatory increase of functional β-cell mass to counter act insulin resistance. 
Interestingly, only overexpression of IRS2 but not of IRS1 or Shc increased 
proliferation in β-cells. This points to the importance of cellular context for the effect 
of the different members of the IRS family and thus might explain the discrepancy 
between the results presented here and previous results [14, 20]. 
However, the effects of naturally occurring or experimentally induced variations in the 
cellular content of IRS proteins underline their importance in the regulation of cell 
proliferation and cellular function. Upregulation of IRS2 has been observed in 
metastatic variants of breast cancer cell lines [32], in pancreatic cancers [33], and 
recently in hepatocellular carcinoma [34]. Transgenic mice with targeted hepatic 
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overexpression of IRS1 displayed increased liver size and glycogen content [35], 
transgenic two fold increase in expression of IRS2 in murine B cells [35] did not 
increase B cell proliferation, but altered Ig production. In light of our findings that high 
level expression of IRS proteins can trigger signal transduction independent of 
ligand-activated receptors, it appears likely that increased expression of IRS1/2 and 
maybe also IRS3/4 could play instructive rather then just permissive roles in the 
control of metabolism, cell growth, proliferation and apoptosis.  
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Figure 1: Mutations within the juxtamembrane region of the insulin receptor 
modulate binding of IRS1 and receptor tyrosine phosphorylation. (A) Myc-
tagged IRS1 was co-overexpressed in HEK 293 cells either with green fluorescent 
protein (GFP) as control or with CSF/IR hybrid receptors containing the indicated 
juxtamembrane motifs. 40 h after transfection, cells were starved for 4 h, stimulated 
with 10 nM M-CSF for 10 min and subsequently lysed. Expression levels of myc-
tagged IRS1 were assessed in total lysates by Western blotting with α myc 
antibodies (upper panel). CSF/IR hybrid receptors and associated IRS1 were co-
precipitated from lysates with antibodies recognizing the β-chain of the insulin 
receptor. Immunoblots prepared from precipitates were analysed with the indicated 
(on the left) antibodies to detect amount and phosphorylation state of CSF/IR hybrid 
receptor (third and fourth panel, respectively) and co-immunoprecipitating myc-
tagged IRS1 (second panel). (B) Quantification of tyrosine phosphorylation of CSF/IR 
and of the amount of precipitated IRS1. The degree of tyrosine phosphorylation is 
presented as the ratio between signals of phospho-CSF/IR and total CSF/IR (P-
CSF/IR : CSF/IR). Signal intensities were determined using AIDA software (raytest, 
Switzerland).  
 
Figure 2: Overexpression of IRS1 and IRS2 but not of Shc results in ligand-
independent insulin receptor tyrosine phosphorylation. (A) 0.5 μg of plasmid 
coding for the insulin receptor was co-transfected with the indicated amounts of 
plasmid coding for IRS1 (lanes 1-6), IRS2 (lanes 7-12) or Shc (lanes 13-18) into 
CHO-K1 cells. Control plasmid coding for GFP was added to a total amount of 2.5 μg 
plasmid-DNA per transfection. 20 h after transfection, cells were starved for 4 h, 
stimulated with 100 nM insulin for 3 min and subsequently lysed. Tyrosine 
phosphorylated proteins were detected by immunoblotting using a monoclonal anti-
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phospho-tyrosine antibody (α pY) (upper panel). Expression levels of the insulin 
receptor were detected with an antibody directed against the β-chain (lower panel). 
The graph shows a quantification of signal intensities of phosphorylated beta chain 
(determined as in Fig. 1B) (B) The degree of overexpression of IRS1, IRS2 and Shc 
was determined using antibodies against IRS1 (upper panel), IRS2 (middle panel) 
and Shc (lower panel). One representative blot of three independent experiments is 
shown. 
 
Figure 3: Only overexpression of full-length IRS1 can efficiently increase 
insulin receptor tyrosine phosphorylation. (A) Schematic representation of the 
IRS1 fragments that were overexpressed as C-terminal myc tag fusions in CHO-K1 
cells. Expression was driven by the CMV promoter. (B and C) 0.5 μg of plasmid 
coding for the insulin receptor was co-transfected into CHO-K1 cells with the 
indicated amounts of plasmid coding for full-length IRS1 or for the indicated 
fragments of IRS1. Control plasmid coding for GFP (c) was added to bring the total 
amount of DNA per transfection to 2.5 μg. 20 h after transfection, cells were starved 
for 4 h, stimulated with 100 nM insulin for 3 min and subsequently lysed. Total lysates 
were analysed by Western blotting with the indicated antibodies (on the left) to detect 
tyrosine phosphorylation (upper panel), expression of the insulin receptor (middle 
panel) and expression of IRS1 and its fragments (lower panel). Graphs show 
quantification of phosphorylation of the beta chain relative to total amount of beta 
chain.  
 
Figure 4: Overexpression of IRS1 and IRS2 increase phosphorylation of the IR 
by inhibiting receptor internalisation. (A) Internalisation of [125I] labelled (tracer) 
insulin in CHO-IR cells. Cells were either untreated (c), pre-treated with 0.4 M 
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sucrose (s) or infected with the indicated amounts of adenoviral constructs encoding 
myc-tagged IRS1, IRS2 or Shc. The Western blot on the right shows the relative 
expression levels of myc-tagged IRS1, IRS2 and Shc after immunoblotting with α 
myc antibody. Two exposure times of the same membrane are shown. (B) 
Hyperosmolar sucrose increases insulin receptor tyrosine phosphorylation. CHO-IR-
cells were starved for 4 h. 20 min prior to stimulation, medium was replaced by 
starvation medium containing 0.4 M sucrose or by fresh starvation medium. After the 
indicated period of stimulation with 10 nM insulin, cells were lysed and tyrosine 
phosphorylation of the insulin receptor was determined by immunoblotting with 
antibodies against phosphorylated tyrosine residues (α pY, upper panel). Expression 
of the insulin receptor was assessed using an antibody against the β-chain of the 
insulin receptor (lower panel). 
 
Figure 5: Overexpression of IRS1 and IRS2 increases the activation of Akt but 
represses Erk 1/2. (A) CHO-K1 cells were co-transfected with 0.5 μg of plasmid 
encoding the human insulin receptor and with either 2 μg plasmid encoding GFP (c) 
or myc-tagged IRS1, IRS2 or Shc, as indicated. 20 h after transfection, cells were 
starved for 4h, stimulated with the indicated amounts of insulin for 4 minutes and 
subsequently lysed. The activation state of Akt was determined by Western blotting 
using an antibody specific for its phosphorylated (ser473) form (first panel). The 
activation state of Erk 1/2 was determined using an α-phospho Erk 1/2 antibody 
(second panel). Expression of the insulin receptor was determined with antibodies 
against the β-chain of the insulin receptor (third panel). The relative expression of 
IRS1 and IRS2 was determined with an antibody against the myc-tag (fourth panel) 
while the degree of overexpression of IRS1, IRS2 and Shc was determined using 
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antibodies recognizing IRS1 (fifth panel), IRS2 (sixth panel) and Shc (seventh panel). 
(B) CHO-IR cells ectopically expressing HIS-tagged IRS1, IRS2, Shc or GFP as a 
control were stimulated with insulin as indicated, lysed and lysates were incubated 
with Ni-NTA to test for co-purification of p85 and Grb2. Signals for Shc in the myc-
blot were cut-out from the exposure and placed at the same position as IRS1/2 in the 
graph.  
 
Figure 6: Overexpression of IRS1 and IRS2 increases ligand-dependent and 
ligand-independent [3H]-thymidin incorporation in CHO-IR cells.  
CHO-IR cells were infected and starved as described in materials and methods and 
incubated with or without insulin and [3H]-thymidine for 4 h. Three sets of 
experiments were performed (A-C) and each graph represents a summary of the 
series where data are expressed as percent of control (cells without viral infection). 
Adenovirus encoding GFP was used to assess viral effects in each of the 
experiments. * p<0.05 by unpaired two-sided t-test. (A) Overexpression of IRS1 and 
IRS2, but not Shc, induced DNA synthesis independent of and synergistically with 
insulin (n=5). (B) Overexpression of full length IRS1 significantly increased [3H]-
thymidine incorporation independent of hormone, while none of the fragments 
showed this effect (n=4). Overexpression of the IRS1 PH-PTB domain significantly 
suppressed basal and insulin-induced DNA synthesis. (C) Combined overexpression 
of IRS1 and two of its subfragments (PH-PTB domains and C-term) repressed IRS1-
dependent [3H]-thymidine incorporation, while the C-term did not prevent insulin-
induced [3H]-thymidine incorporation. 
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